Published in Int J Immunopharmacol on January 01, 1987
Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide). Proc Natl Acad Sci U S A (1993) 1.00
An overview of clinical trials involving inhibitors of angiogenesis and their mechanism of action. Invest New Drugs (1997) 0.82
Linomide blocks angiogenesis by breast carcinoma vascular endothelial growth factor transfectants. Br J Cancer (1998) 0.78
Enhanced lymphokine-activated killer cell activity by an immunomodulator, Roquinimex. Br J Cancer (1995) 0.75
A feasibility study of roquinimex (Linomide) and alpha interferon in patients with advanced malignant melanoma or renal carcinoma. Br J Cancer (1998) 0.75
Effect of the synthetic immunomodulator, linomide, on experimental models of thyroiditis. Immunology (1999) 0.75
Promising approaches in acute leukemia. Invest New Drugs (2000) 0.75
Two distinct factors are required for induction of T-cell growth. Nature (1980) 4.13
The role of mitogenic lectins in T-cell triggering. Nature (1979) 3.26
Cyclosporin A and dexamethasone suppress T cell responses by selectively acting at distinct sites of the triggering process. J Immunol (1980) 2.77
Studies on T lymphocyte activation. I. Requirements for the mitogen-dependent production of T cell growth factors. Eur J Immunol (1979) 2.59
Mechanism of T cell activation. II. Antigen- and lectin-dependent acquisition of responsiveness to TCGF is a nonmitogenic, active response of resting T cells. J Immunol (1981) 2.10
Studies on T lymphocyte activation II. The target cells for concanavalin A-induced growth factors. Eur J Immunol (1979) 2.10
Effects of buprenorphine on body temperature, locomotor activity and cardiovascular function when assessed by telemetric monitoring in rats. Lab Anim (2008) 1.49
Autonomous activation of B and T cells in antigen-free mice. Eur J Immunol (1986) 1.29
Functional consequences of sheep red blood cell rosetting for human T cells: gain of reactivity to mitogenic factors. Eur J Immunol (1978) 1.20
Regulation of T cell growth factor production: arrest of TCGF production after 18 hours in normal lectin-stimulated mouse spleen cell cultures. J Immunol (1981) 1.18
A suggested mechanism for T lymphocyte activation: implications on the acquisition of functional reactivities. Immunol Rev (1980) 1.15
Differential requirements for activation and growth of unprimed cytotoxic and helper T lymphocytes. Eur J Immunol (1983) 1.12
Studies on induction and effector functions of concanavalin A-induced suppressor cells that limit TCGF production. J Immunol (1982) 1.09
Mechanism of T cell activation. I. A screening of "step one" ligands. Eur J Immunol (1980) 1.03
Quantitative studies on concanavalin A-induced, TCGF-reactive T cells. I. Correlation between proliferation and lectin-dependent cytolytic activity. J Immunol (1981) 0.99
Internal complementarities in the immune system: regulation of the expression of helper T-cell idiotypes. Proc Natl Acad Sci U S A (1984) 0.98
Successful treatment of autoimmunity in MRL/1 mice with LS-2616, a new immunomodulator. Arthritis Rheum (1986) 0.97
Functional heterogeneity of helper T cells: two distinct helper T cells are required for the production of T cell growth factor. J Immunol (1982) 0.95
Effects of LS-2616 administration upon the autoimmune disease of (NZB x NZW) F1 hybrid mice. Immunology (1986) 0.95
"In vivo" activated splenic T cells are refractory to interleukin 2 growth "in vitro". Eur J Immunol (1987) 0.94
Natural effector T lymphocytes in normal mice. Proc Natl Acad Sci U S A (1985) 0.91
One third of murine splenic T cells are cytotoxic precursors induced to grow by leucoagglutinin and TCGF. Scand J Immunol (1981) 0.90
Immunosuppression after measles vaccination. Acta Paediatr (1994) 0.89
Macrophage requirement for production of the human mitogenic factor in vitro. Scand J Immunol (1978) 0.88
Requirement for the involvement of clonally distributed receptors in the activation of cytotoxic T lymphocytes. Immunol Rev (1982) 0.86
Degeneracy of H-2 recognition by cytotoxic T lymphocytes: 10% of the total repertoire is "specific" for a given haplotype and up to 1% is self-H-2 reactive. Eur J Immunol (1986) 0.86
Effects of hydroxyurea on concanavalin-A-induced T-cell proliferation. Depletion of T-cell growth factor-reactive and -producing T lymphocytes. Scand J Immunol (1984) 0.84
Con A-induced TCGF-reactivity is selectively acquired by Lyt-2-positive T cell precursors. J Immunol (1983) 0.84
Major histocompatibility complex class I-binding peptides are recycled to the cell surface after internalization. Eur J Immunol (1993) 0.83
Clonal specificity of concanavalin A-induced cytotoxic T lymphocytes. Eur J Immunol (1985) 0.82
Development of an instrument for clinical evaluation after surgery for neuromuscular scoliosis. Eur Spine J (1996) 0.82
Effects of the novel immunomodulator LS 2616 on the delayed-type hypersensitivity reaction to Bordetella pertussis in the rat. Immunopharmacology (1986) 0.82
On the role of I-A antigens in lectin- and antigen-induced interleukin 2 production. Eur J Immunol (1984) 0.80
Nicotyrine inhibits in vivo metabolism of nicotine without increasing its toxicity. Toxicol Appl Pharmacol (1982) 0.80
Metabolism in vitro of 14C-nicotine in livers of foetal, newborn and young mice. Acta Pharmacol Toxicol (Copenh) (1969) 0.80
Selective effects of interferon on distinct sites of the T lymphocyte triggering process. J Immunol (1982) 0.80
Induction of cytolytic T lymphocytes by mitogenic lectins is specifically inhibited by anti-Lyt-2 antibodies. Eur J Immunol (1983) 0.79
Selective inhibition of antigen-induced "step one" in cytotoxic T lymphocytes by anti-Lyt-2 antibodies. Eur J Immunol (1982) 0.78
Effects of increased liver metabolism of nicotine on its uptake, elimination and toxicity in mice. Acta Physiol Scand (1970) 0.78
Ionophore A23-187 induces responses to TCGF in mouse lymphocytes. Ann Immunol (Paris) (1984) 0.78
Wheat germ agglutinin activates macrophages for collaboration with B cells. Eur J Immunol (1979) 0.78
Activation and growth requirements for cytotoxic and noncytotoxic T lymphocytes. Cell Immunol (1984) 0.78
Heterogeneity of cells and factors participating in the concanavalin A-dependent activation of T lymphocytes with cytotoxic potential. Immunobiology (1982) 0.77
Amelioration of intrathymic T cell development and peripheral T cell reactivities in autoimmune mice undergoing therapy with a novel immunomodulator. Int Immunol (1990) 0.77
Characterization of a human mitogenic factor (MF) released by phytohemagglutinin-activated lymphocytes. Cell Immunol (1979) 0.77
Effect of nicotine treatment on the metabolism of nicotine in the mouse liver in vitro. Acta Pharmacol Toxicol (Copenh) (1970) 0.77
Lack of antiinflammatory activity of metronidazole. Acta Pharmacol Toxicol (Copenh) (1981) 0.77
Evidence that soluble products released by PHA-stimulated human lymphoid cells activate immunosuppressive monocytes. Scand J Immunol (1979) 0.77
Regulation of lymphocyte proliferation by soluble products released by stimulated human lymphocytes. Int Arch Allergy Appl Immunol (1978) 0.77
Affinity chromatography of neoglycoproteins. Bioseparation (2000) 0.77
Separation of mistletoe lectins based on the degree of glycosylation using boronate affinity chromatography. J Chromatogr A (2001) 0.76
Interleukin-2 (IL-2) and its receptor. Med Oncol Tumor Pharmacother (1986) 0.76
The metabolism of nicotine and cotinine by a mouse liver preparation. Acta Physiol Scand (1970) 0.75
Lethal brain concentrations of nicotine in mice of different ages. Acta Pharmacol Toxicol (Copenh) (1970) 0.75
Naming lymphocytespecific growth and differentiation factors. Immunol Today (2007) 0.75
Indications for an internal regulation in the immune system. Prog Clin Biol Res (1980) 0.75
Factors affecting the uptake, elimination and toxicity of nicotine in the mouse. Acta Pharmacol Toxicol (Copenh) (1967) 0.75
Selective functional role of murine Tm and Tg cells in concanavalin-A-induced T-cell activation. Scand J Immunol (1983) 0.75
Internal activity of the immune system and its physiologic significance. Haematol Blood Transfus (1985) 0.75
Evidence that nonspecific inhibitors are induced by soluble products of activated human lymphocytes. Int Arch Allergy Appl Immunol (1978) 0.75
Effects of the antiviral WIN 54954 and the immune modulator LS 2616 on cachectin/TNF and gamma-interferon responses during viral heart disease. Scand J Infect Dis Suppl (1993) 0.75
The cytotoxic T-cell response to Ia antigens: lack of correlation between the level of specific cytotoxicity obtained in primary mixed lymphocyte reaction and the frequency of specific cytotoxic T lymphocyte. Scand J Immunol (1986) 0.75
Detection of cell-mediated lympholysis determinants encoded by the I-A and I-E genes on ultraviolet-irradiated spleen cells. Scand J Immunol (1985) 0.75
Whole-blood microassay for immunodetection of antigen specific cell mediated immunity using bromodeoxyuridine incorporation. J Clin Lab Immunol (1991) 0.75
In vitro metabolism of nicotine in liver of ageing mice. Arch Int Pharmacodyn Ther (1977) 0.75
Development of a model system for analysing graft-versus-host-mediated immune suppression. Scand J Immunol (1986) 0.75
Cardiovascular effects of xylazine recorded with telemetry in the dog. J Vet Med A Physiol Pathol Clin Med (2003) 0.75
Effects of EDTA on trace elements and cardiovascular function in the anesthetised rabbit. Biol Trace Elem Res (2000) 0.75
From the mechanisms of lymphocyte activation to internal activity in the immune system. Ann Immunol (Paris) (1983) 0.75
Age dependent changes in nicotine distribution in the brain of the mouse. Acta Pharmacol Toxicol (Copenh) (1972) 0.75
Activation of Lyt-2+ T cells by antibodies towards brain-associated antigens. I. Accessory cell requirement and role of Fc receptors in the induction of reactivity to interleukin 2. Eur J Immunol (1985) 0.75